Immediate Impact
4 hit
Citing Papers
A snapshot of the PD-1/PD-L1 pathway
2021 Hit
LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers
2019 Hit
Works of Meagan S. Barbee being referenced
Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology
2015
Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer
2015